Novel concepts and combinations for high-risk AML

Updates from ASH 2018

ASH 2018: A promising future for high-risk AML patients

Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX gives an update on the exciting news in acute myeloid leukemia (AML) from ASH 2018. With the fast approval of novel agents such as FLT3, IDH and BCL-2 inhibitors, and the combination of these agents with high-dose chemotherapy and hypomethylating agents, this is an extremely promising time for high-risk AML patients

HDAC inhibitors for AML: a platform on which to build other compounds and combinations?

Prof. Garcia-Manero discusses how HDAC inhibitors fit within the AML treatment landscape, talking about the encouraging future of the phase III pracinostat trial for older patients with high-risk AML. This trial has the potential to open the door for multiple interesting combinations.